Tirzepatide associated with a potential targeted effect on visceral fat and liver fatExploratory analysis from the SURPASS-3 MRI study has shown a significant reduction of both visceral- and liver fat z-scores, and a shift...
Semaglutide and tirzepatide decrease cravings and reduce alcohol consumptionAn analysis of social media posts and a remote study of individuals with obesity who reported using semaglutide and tirzepatide, has...
Journal Watch 01/11/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Journal Watch 07/06/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Journal Watch 31/05/2023Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
SURMOUNT-1: Tirzepatide results in 22.5% weight loss in adults with obesity or overweightTirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure5 days ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity5 days ago